Logo image of CRON.CA

CRONOS GROUP INC (CRON.CA) Stock Fundamental Analysis

Canada - TSX:CRON - CA22717L1013 - Common Stock

3.6 CAD
-0.1 (-2.7%)
Last: 9/19/2025, 7:00:00 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to CRON. CRON was compared to 34 industry peers in the Pharmaceuticals industry. While CRON has a great health rating, there are worries on its profitability. CRON is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year CRON was profitable.
In the past year CRON had a positive cash flow from operations.
In the past 5 years CRON reported 4 times negative net income.
In the past 5 years CRON reported 4 times negative operating cash flow.
CRON.CA Yearly Net Income VS EBIT VS OCF VS FCFCRON.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

The Return On Assets of CRON (1.57%) is better than 85.29% of its industry peers.
CRON's Return On Equity of 1.71% is amongst the best of the industry. CRON outperforms 82.35% of its industry peers.
Industry RankSector Rank
ROA 1.57%
ROE 1.71%
ROIC N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
CRON.CA Yearly ROA, ROE, ROICCRON.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

The Profit Margin of CRON (14.19%) is better than 91.18% of its industry peers.
CRON's Profit Margin has declined in the last couple of years.
CRON has a Gross Margin (32.74%) which is in line with its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 14.19%
GM 32.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
CRON.CA Yearly Profit, Operating, Gross MarginsCRON.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

More info and screens

8

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRON has more shares outstanding than it did 1 year ago.
CRON has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRON.CA Yearly Shares OutstandingCRON.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
CRON.CA Yearly Total Debt VS Total AssetsCRON.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 7.86 indicates that CRON is not in any danger for bankruptcy at the moment.
The Altman-Z score of CRON (7.86) is better than 97.06% of its industry peers.
There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.86
ROIC/WACCN/A
WACC9.08%
CRON.CA Yearly LT Debt VS Equity VS FCFCRON.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 24.65 indicates that CRON has no problem at all paying its short term obligations.
The Current ratio of CRON (24.65) is better than 100.00% of its industry peers.
A Quick Ratio of 23.53 indicates that CRON has no problem at all paying its short term obligations.
CRON has a better Quick ratio (23.53) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 24.65
Quick Ratio 23.53
CRON.CA Yearly Current Assets VS Current LiabilitesCRON.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

6

3. Growth

3.1 Past

CRON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 162.50%, which is quite impressive.
CRON shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -50.78% yearly.
Looking at the last year, CRON shows a very strong growth in Revenue. The Revenue has grown by 28.01%.
The Revenue has been growing by 37.71% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)162.5%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%-400%
Revenue 1Y (TTM)28.01%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%20.51%

3.2 Future

Based on estimates for the next years, CRON will show a very negative growth in Earnings Per Share. The EPS will decrease by -21.14% on average per year.
CRON is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.39% yearly.
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue Next Year12.95%
Revenue Next 2Y21.44%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CRON.CA Yearly Revenue VS EstimatesCRON.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CRON.CA Yearly EPS VS EstimatesCRON.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CRON is valuated quite expensively with a Price/Earnings ratio of 51.43.
Based on the Price/Earnings ratio, CRON is valued a bit cheaper than 79.41% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.38, CRON is valued quite expensively.
Based on the Price/Forward Earnings ratio of 36.50, the valuation of CRON can be described as expensive.
CRON's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CRON is cheaper than 73.53% of the companies in the same industry.
CRON is valuated expensively when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 51.43
Fwd PE 36.5
CRON.CA Price Earnings VS Forward Price EarningsCRON.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRON.CA Per share dataCRON.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.5%
EPS Next 3Y3.91%

More info and screens

0

5. Dividend

5.1 Amount

CRON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRONOS GROUP INC

TSX:CRON (9/19/2025, 7:00:00 PM)

3.6

-0.1 (-2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners13.12%
Inst Owner ChangeN/A
Ins Owners6.2%
Ins Owner ChangeN/A
Market Cap1.38B
Analysts82.86
Price Target2.4 (-33.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-0.31%
Max Revenue beat(2)-0.21%
Revenue beat(4)1
Avg Revenue beat(4)-1.44%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)9.73%
Revenue beat(8)4
Avg Revenue beat(8)1.96%
Revenue beat(12)4
Avg Revenue beat(12)-3.07%
Revenue beat(16)7
Avg Revenue beat(16)-2.54%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)65.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.63%
Valuation
Industry RankSector Rank
PE 51.43
Fwd PE 36.5
P/S 7.66
P/FCF N/A
P/OCF 49.82
P/B 0.92
P/tB 0.99
EV/EBITDA N/A
EPS(TTM)0.07
EY1.94%
EPS(NY)0.1
Fwd EY2.74%
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)0.07
OCFY2.01%
SpS0.47
BVpS3.91
TBVpS3.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.57%
ROE 1.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 14.19%
GM 32.74%
FCFM N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 224.14%
Cap/Sales 22.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.65
Quick Ratio 23.53
Altman-Z 7.86
F-Score7
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.5%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%-400%
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)28.01%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%20.51%
Revenue Next Year12.95%
Revenue Next 2Y21.44%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
EBIT growth 1Y42.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.02%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y90.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y120.6%
OCF growth 3YN/A
OCF growth 5YN/A